Trial: 202009029

A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigators Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)



Principal Investigator

Bagegni, Nusayba

Disease Site

Breast; Metastatic Disease

Learn more about this study at: